Adjuvant radiochemotherapy has lasting benefit in gastric cancer

May 18, 2012
Adjuvant radiochemotherapy has lasting benefit in gastric cancer

(HealthDay) -- Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival (OS) and relapse-free survival (RFS), according to research published online May 14 in the Journal of Clinical Oncology.

Stephen R. Smalley, M.D., of the Radiation Oncology Center of Olathe, Kan., and colleagues updated follow-up data from the Southwestern Oncology Group-directed Intergroup Study 0116 phase III trial involving 559 patients with who were treated with either adjuvant radiochemotherapy or observation after resection. Participants were at moderate risk of locoregional failure after surgery, and results were presented after a median of more than 10 years of follow-up.

The researchers found that adjuvant radiochemotherapy continued to demonstrate strong benefit in both OS and RFS (hazard ratio, 1.32 and 1.51, respectively), except in the subset of patients with diffuse histology. Secondary malignancies were seen in more patients treated with radiotherapy than observation, but the difference was not significant (P = 0.21).

"The authors conclude that the observed benefits appear to outweigh a possible increased risk of second . In light of the documented survival benefits after 10 years of follow-up, this conclusion seems reasonable," write the authors of an accompanying editorial.

One study author received funding from Pathfinder. The authors of the editorial disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Early response is an indicator for rectal cancer survival

April 10, 2012

(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, distant metastases, ...

High survival with surgery in low-risk neuroblastoma

April 25, 2012

(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

Adjuvant therapy shows promise in biliary tract cancer

April 27, 2012

(HealthDay) -- For patients with biliary tract cancers, postresection adjuvant therapy with chemotherapy or chemoradiotherapy appears to be beneficial in treating patients with biliary tract cancers, with significant improvement ...

Recommended for you

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.